Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Data integrity has no relationship with product quality
Peter J. Werth, President and Chief Executive Officer, ChemWerth, a US-headquartered full-service ge
Zhejiang Hisun’s FDA import alert; a new chapter in the fight against data integrity
A few months ago, PharmaCompass covered
the Health Canada request to quarantine drugs linked to lead
